Document Detail

First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
MedLine Citation:
PMID:  22898359     Owner:  NLM     Status:  Publisher    
BACKGROUND: The dose of mifepristone approved by most government agencies for medical abortion is 600 mg. Our aim was to summarize extant data on the effectiveness and safety of regimens using the widely recommended lower mifepristone dose, 200 mg, followed by misoprostol in early pregnancy and to explore potential correlates of abortion failure. STUDY DESIGN: To identify eligible reports, we searched Medline, reviewed reference lists of published reports, and contacted experts to identify all prospective trials of any design of medical abortion using 200 mg mifepristone followed by misoprostol in women with viable pregnancies up to 63 days' gestation. Two authors independently extracted data from each study. We used logistic regression models to explore associations between 15 characteristics of the trial groups and, separately, the rates of medical abortion failure and of ongoing pregnancy. RESULTS: We identified 87 trials that collectively included 120 groups of women treated with a regimen of interest. Of the 47,283 treated subjects in these groups, abortion outcome data were reported for 45,528 (96%). Treatment failure occurred in 2,192 (4.8%) of these evaluable subjects. Ongoing pregnancy was reported in 1.1% (499/45,150) of the evaluable subjects in the 117 trial groups reporting this outcome. The risk of medical abortion failure was higher among trial groups in which at least 25% of subjects had gestational age >8 weeks, the specified interval between mifepristone and misoprostol was less than 24 h, the total misoprostol dose was 400 mcg (rather than higher), or the misoprostol was administered by the oral route (rather than by vaginal, buccal, or sublingual routes). Across all trials, 119 evaluable subjects (0.3%) were hospitalized, and 45 (0.1%) received blood transfusions. CONCLUSIONS: Early medical abortion with mifepristone 200 mg followed by misoprostol is highly effective and safe.
Elizabeth G Raymond; Caitlin Shannon; Mark A Weaver; Beverly Winikoff
Related Documents :
16374219 - Management of genital infections in pregnant women.
21950269 - Recommendations for the prevention of pregnancy-associated venous thromboembolism.
7195529 - Management of genital herpes simplex virus infection during pregnancy.
8433879 - Maternofetal transmission of human immunodeficiency virus-1: the role of antibodies to ...
22182369 - Spontaneous procreation in turner syndrome: report of two pregnancies in the same patient.
10826579 - An epidemic of parvovirus b19 in a population of 3,596 pregnant women: a study of socio...
23320899 - Environmental risk factors of pregnancy outcomes: a summary of recent meta-analyses of ...
15140509 - Amniotic levels of nitric oxide and vascular endothelial growth factor in pregnancy wit...
3332039 - Routine antenatal ultrasound: a retrospective audit.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-13
Journal Detail:
Title:  Contraception     Volume:  -     ISSN:  1879-0518     ISO Abbreviation:  Contraception     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Gynuity Health Projects, 15 East 26th Street, Suite 801, New York, NY 10010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An exploratory, randomized, crossover MRI study of microbicide delivery with the SILCS diaphragm com...
Next Document:  Pharmacokinetic profile of nomegestrol acetate and 17?-estradiol after multiple and single dosing in...